Sugi Predict

Sugi Predict / Compounds / SCHEMBL3095143

SCHEMBL3095143

SCHEMBL3095143

Fc1ccc2oc(Cl)nc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MPO P05164 1/20 0.45
▸ LMNA P02545 2/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ THRB P10828 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ FBP1 P09467 1/20 0.42
▸ GABRP O00591 3/20 0.40
▸ GABRD O14764 3/20 0.40
▸ GABRA1 P14867 3/20 0.40
▸ GABRB1 P18505 3/20 0.40
▸ GABRG2 P18507 3/20 0.40
▸ GABRB3 P28472 3/20 0.40
▸ GABRA5 P31644 3/20 0.40
▸ GABRA3 P34903 3/20 0.40
▸ GABRA2 P47869 3/20 0.40
▸ GABRB2 P47870 3/20 0.40
▸ GABRA4 P48169 3/20 0.40
▸ GABRE P78334 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3950849 0.84 PIK3CG (0.43) MAPTGABRPGABRDGABRA1GABRB1
SCHEMBL1672481 0.79 LMNA (0.66) LMNACYP1A2MAPTTHRBALOX15
SCHEMBL30300530 0.76 L3MBTL1 (0.56) MPOLMNAMAPTMAPK1GABRP
SCHEMBL31119203 0.76 LMNA (0.61) MPOLMNACYP1A2MAPTTHRB
SCHEMBL2061652 0.76 L3MBTL1 (0.56) MPOLMNAMAPTMAPK1GABRP
SCHEMBL5547324 0.76 MPO (0.45) MPOLMNACYP1A2MAPTTHRB
SCHEMBL4454889 0.76 MPO (0.45) MPOLMNACYP1A2MAPTTHRB
SCHEMBL137387 0.76 RAB9A (0.58) LMNAMAPTFBP1SMN1; SMN2CASP3
SCHEMBL30897543 0.76 MPO (0.45) MPOLMNACYP1A2MAPTTHRB
SCHEMBL29593303 0.76 MPO (0.45) MPOLMNACYP1A2MAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117120423-B Indolylamine 2, 3-dioxygenase inhibitors, methods of preparing the same, and pharmaceutical compositions containing the same 柳韩洋行 2026-02-27 — — CN disclosed
EP-4634175-A1 BENZIMIDAZOLE DERIVATIVES Immvention Therapeutix, Inc. (US) 2025-10-22 — — EP disclosed
US-12297209-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2025-05-13 — — US disclosed
US-12268694-B2 Combination pharmaceutical agents as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2025-04-08 — — US disclosed
WO-2025050125-A1 SUBSTITUTED BENZOXAZOLYLAMINO BENZOXAZOLES IMMVENTION THERAPEUTIX (US) 2025-03-06 — — WO disclosed
CN-113382767-B Urea compounds having substituents 第一三共株式会社 2024-12-24 — — CN disclosed
US-20240360155-A1 Benzodiazepine Derivatives as RSV Inhibitors ENANTA PHARM INC (US) 2024-10-31 — — US disclosed
WO-2024130173-A1 BENZIMIDAZOLE DERIVATIVES IMMVENTION THERAPEUTIX (US) 2024-06-20 — — WO disclosed
US-20240174636-A1 NOVEL INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2024-05-30 — — US disclosed
US-11981686-B2 Urea compound having substituent DAIICHI SANKYO COMPANY, LIMITED (JP) 2024-05-14 — — US disclosed
US-6495549-B1 1-HETEROARYL-PIPERIDINE DERIVATIVES; MODERATING NEURONAL DEGENERATION; PROMOTING NEURONAL REGENERATION AND OUTGROWTH; TREATOG NEUROLOGICAL DISORDERS ARISING FROM NEURODEGENERATIVE DISEASES OR OTHER DISORDERS INVOLVING NERVE DAMAGE PFIZER INC 2002-12-17 — — US disclosed
EP-1098894-B1 FKBP INHIBITORS PFIZER LTD (GB) 2002-10-02 — — EP disclosed
EP-0883611-B1 AZOLYL PIPERAZINYL PHENYL OXAZOLIDINONE ANTIMICROBIALS UPJOHN CO (US) 2002-07-31 — — EP disclosed
EP-1098894-A1 FKBP INHIBITORS Pfizer Limited (GB) 2001-05-16 — — EP disclosed
WO-2000005231-A1 FKBP INHIBITORS PFIZER LIMITED (GB) 2000-02-03 — — WO disclosed
EP-0883611-A1 AZOLYL PIPERAZINYL PHENYL OXAZOLIDINONE ANTIMICROBIALS PHARMACIA & UPJOHN COMPANY (US) 1998-12-16 — — EP disclosed
US-5736545-A ADMINISTERING TO TREAT BACTERIAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 1998-04-07 — — US disclosed
WO-1997030981-A1 AZOLYL PIPERAZINYL PHENYL OXAZOLIDINONE ANTIMICROBIALS PHARMACIA & UPJOHN COMPANY (US) 1997-08-28 — — WO disclosed
EP-0572893-A1 Fluor-benzoxazolyloxyacetamides BAYER AG (DE) 1993-12-08 — — EP disclosed
EP-0500934-A1 ARALKYLOXYAMINE DERIVATIVE AND HERBICIDE HOKKO CHEMICAL INDUSTRY CO. LTD. (JP) 1992-09-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240174636-A1 NOVEL INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME IDO1, IDO2, INMT MPO 257/4885LMNA 4438/4885CYP1A2 128/4885
US-11981686-B2 Urea compound having substituent SIRT6, SIRT1, SIRT2 MPO 710/4885LMNA 3589/4885CYP1A2 3672/4885
US-20240360155-A1 Benzodiazepine Derivatives as RSV Inhibitors GABRA5, GABRA1, GABBR2 MPO 3195/4885LMNA 2153/4885CYP1A2 58/4885
US-12297209-B2 Benzodiazepine derivatives as RSV inhibitors GABRA5, GABRA1, GABBR2 MPO 3195/4885LMNA 2153/4885CYP1A2 58/4885
US-12268694-B2 Combination pharmaceutical agents as RSV inhibitors ACE, ACE2, SPCS3 MPO 1624/4885LMNA 3454/4885CYP1A2 4518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.